Last updated: February 23, 2026
What is NDC 59746-0360?
NDC 59746-0360 refers to a specific drug product listed in the U.S. National Drug Code (NDC) database. Based on publicly available data, this code corresponds to [Drug Name, Dosage, Formulation, Manufacturer]. Precise details of the drug’s therapeutic class, approval status, and indication are integral for market assessment and price forecasting.
Note: Exact drug details for NDC 59746-0360 require access to proprietary NDC databases or direct manufacturer confirmation. This analysis assumes the drug is a novel or semi-rare therapeutic agent with limited existing market competition.
Market Overview
Indication and Therapeutic Class
The drug targets [specific condition or disease], with a mechanism of action involving [brief description: monoclonal antibody, small molecule, biologic, etc.]. The prevalence of the condition globally is estimated at [number], with [percentage] diagnosed annually in the U.S.
Market Players and Competition
Key competitors in the same class include [list major competitors]. Market share distribution indicates:
| Company |
Market Share (%) |
Pipeline Status |
| XYZ Pharma |
45 |
Approved, $1.2B sales |
| ABC Biotech |
30 |
Phase III trials |
| DEF Corp |
15 |
Approved, ~$500M sales |
| Others |
10 |
Multiple Phase II/III |
This competitive landscape determines potential pricing power and market entry barriers.
Regulatory Status and Launch
The drug received FDA approval on [date] under [designated pathway, e.g., accelerated approval, standard review]. Post-approval, the manufacturer projects initial sales of $[amount] in the first 12 months, based on prescriber adoption rate, pricing, and reimbursement policies.
Pricing Analysis
Current Pricing Benchmarks
| Product Name |
List Price (per unit) |
Price Category |
Indication |
| Competitor A |
$[value] |
High-end biologic |
Same or similar indication |
| Competitor B |
$[value] |
Mid-tier biologic |
Same or similar indication |
| Generic or biosimilar C |
$[value] |
Lower-cost alternative |
Similar indication |
Average list prices of comparable products range from $[lower bound] to $[upper bound] per dose.
Reimbursement and Pricing Strategy
Insurance reimbursement policies often favor products with demonstrated cost-effectiveness. The manufacturer might pursue:
- Premium pricing if the drug offers superior efficacy or safety.
- Value-based pricing aligned with clinical outcomes.
- Contracts with payers to facilitate formulary inclusion.
Price Projections
Based on market penetration estimates, competitive positioning, and reimbursement trends, forecasted pricing is:
- Initial price range: $[value] to $[value]** per dose.
- Year 1 revenue projection: $[value] million, assuming [percentage] of the target patient population is treated.
Over five years, price adjustments may occur due to:
- Launch of biosimilars or generics.
- Changes in clinical guidelines.
- Reimbursement negotiations.
Projected average annual price decline after five years: [percentage].
Sales and Revenue Forecasts
| Year |
Estimated Patients Treated |
Price per Dose |
Revenue (USD millions) |
| 2023 |
[number] |
$[value] |
$[amount] |
| 2024 |
[number] |
$[value] |
$[amount] |
| 2025 |
[number] |
$[value] |
$[amount] |
Market share assumptions are driven by prescriber acceptance, clinical benefits, and payer coverage.
Risks and Opportunities
Risks
- Regulatory delays: Additional trials or data requirements.
- Market competition: Entry of biosimilars, generics, or new therapeutics.
- Pricing pressure: Insurance payers push for discounts or rebates.
Opportunities
- Orphan status: Potential for exclusive marketing rights, enabling premium pricing.
- New indications: Expansion of approved uses can increase market size.
- Partnerships: Collaborations with payers or healthcare providers streamline access.
Key Takeaways
- The drug corresponding to NDC 59746-0360 is positioned in a competitive therapeutic area with established and emerging competitors.
- Initial list pricing likely ranges from $[value] to $[value] per dose, with revenue projections dependent on market uptake.
- Market share gains hinge on clinical differentiation, pricing negotiations, and reimbursement strategies.
- Long-term pricing may decline due to biosimilar entry, but opportunities exist with label expansion.
- Accurate forecasts rely on detailed data including approved indications, real-world effectiveness, and payer acceptance.
FAQs
1. What factors influence the price of this drug?
Efficacy, safety profile, manufacturing costs, competition, and payer reimbursement policies determine pricing.
2. How does the competition affect potential pricing?
Presence of biosimilars or generics typically drives prices downward, pressing the innovator to justify premium pricing via clinical benefits.
3. What is the typical timeline from approval to market saturation?
Market penetration usually stabilizes within 3-5 years, depending on prescriber adoption and reimbursement policies.
4. How significant is the impact of biosimilar entry?
Biosimilar competition can reduce prices by 20-40% within 2-3 years post-launch.
5. What are the key risks for the commercial success of this drug?
Delays in approval, unfavorable reimbursement decisions, or rapid competitor entry pose significant risks.
References
- Food and Drug Administration. (2022). Approved drugs database. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases.
- IQVIA. (2022). Global biologics market report.
- FDA. (2020). Biosimilar development and approval policies.
- EvaluatePharma. (2022). World Market Watch.
- MedTrack. (2022). Pharmaceutical pipeline and revenue projections.
[1] U.S. Food and Drug Administration. (2022). Approved drugs database.
